Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from BriaCell Therapeutics ( (TSE:BCT) ).
On February 18, 2026, BriaCell Therapeutics and its majority-owned subsidiary BriaPro Therapeutics announced an asset purchase agreement under which BriaPro will acquire BriaCell’s exclusive license to develop and commercialize Soluble CD80 for cancer treatment, along with related assets. As consideration, BriaPro will issue 23,972,589 common shares to BriaCell, raising BriaCell’s ownership in BriaPro to about 78%, with closing targeted for around March 12, 2026, pending disinterested shareholder approval and an independent valuation.
BriaCell will also provide BriaPro with a credit facility of up to $3 million to fund research and development of Soluble CD80, which has shown promising anti-tumor activity and immune-boosting effects in animal models. The transaction consolidates control of the Soluble CD80 program within BriaPro while deepening BriaCell’s economic stake, potentially sharpening strategic focus on this novel immunotherapy platform and influencing capital allocation and governance for shareholders of both entities.
The most recent analyst rating on (TSE:BCT) stock is a Hold with a C$5.50 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
The score is held down primarily by weak financial performance (no revenue, widening losses, and significant cash burn with likely ongoing financing needs). Technicals are mixed with some shorter-term strength but negative MACD and a price still far below the 200-day average. Valuation contributes limited support due to a negative P/E and no dividend yield.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care, targeting patients who do not respond to existing treatments. Its majority-owned subsidiary, BriaPro Therapeutics Corp., is a pre-clinical immunotherapy company developing binding agents and proteins designed to enhance the body’s own cancer-fighting cells against tumors.
Both companies operate in the oncology-focused biotech sector, with BriaCell listed on Nasdaq and the TSX and BriaPro concentrating on early-stage research assets such as Soluble CD80. Their work positions them within the competitive immuno-oncology market, where innovation around immune system modulation is a key driver of long-term value and potential partnerships.
Average Trading Volume: 24,507
Technical Sentiment Signal: Sell
Current Market Cap: C$39.52M
See more insights into BCT stock on TipRanks’ Stock Analysis page.